Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 8/20 | 0.45 |
| ▸ | BTK | Q06187 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 2/20 | 0.41 |
| ▸ | CTSK | P43235 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1498493 | 1.00 | DRD2 (0.45) | DRD2BTKEPHX1KDM1AMAOB | |
| SCHEMBL1498384 | 1.00 | DRD2 (0.45) | DRD2BTKEPHX1KDM1AMAOB | |
| SCHEMBL21069649 | 0.92 | BTK (0.48) | DRD2BTKEPHX1KDM1AMAOB | |
| SCHEMBL22362354 | 0.92 | BTK (0.48) | DRD2BTKEPHX1KDM1AMAOB | |
| SCHEMBL3896959 | 0.92 | BTK (0.48) | DRD2BTKEPHX1KDM1AMAOB | |
| SCHEMBL3900620 | 0.92 | BTK (0.48) | DRD2BTKEPHX1KDM1AMAOB | |
| SCHEMBL3900150 | 0.92 | BTK (0.48) | DRD2BTKEPHX1KDM1AMAOB | |
| SCHEMBL707674 | 0.87 | DRD2 (0.46) | DRD2BTKEPHX1KDM1AMAOB | |
| SCHEMBL17598632 | 0.87 | DRD2 (0.46) | DRD2BTKEPHX1KDM1AMAOB | |
| SCHEMBL1670919 | 0.87 | DRD2 (0.46) | DRD2BTKEPHX1KDM1AMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4652161-A1 | 2,4-DIANILINOPYRIMIDINE-BASED AURORA-A KINASE SELECTIVE DEGRADATION INDUCING COMPOUNDS | Uppthera, Inc. (KR) | 2025-11-26 | — | — | EP | disclosed |
| US-20250325673-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2025-10-23 | — | — | US | disclosed |
| US-12421191-B2 | 3-hydroxyoxindole derivatives as CRHR2 antagonist | RAQUALIA PHARMA INC. (JP) | 2025-09-23 | — | — | US | disclosed |
| EP-4613773-A2 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2025-09-10 | — | — | EP | disclosed |
| US-12390451-B2 | Small molecule inhibitor of the JAK family of kinases | JANSSEN PHARMACEUTICA NV (BE) | 2025-08-19 | — | — | US | disclosed |
| EP-3731869-B1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2025-07-23 | — | — | EP | disclosed |
| US-20250163061-A1 | INHIBITORS OF MENIN-MLL INTERACTION | BALA THERAPEUTICS, INC. | 2025-05-22 | — | — | US | disclosed |
| US-12202831-B2 | Small molecule inhibitors of the JAK family of kinases | JANSSEN PHARMACEUTICA NV (BE) | 2025-01-21 | — | — | US | disclosed |
| US-20250000985-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-01-02 | — | — | US | disclosed |
| US-12168057-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2024-12-17 | — | — | US | disclosed |
| WO-2012101013-A1 | SUBSTITUTED PYRIDINYL-PYRIMIDINES AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-02 | — | — | WO | disclosed |
| EP-2477963-A1 | ARYL SULPHONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | Zalicus Pharmaceuticals Ltd. (CA) | 2012-07-25 | — | — | EP | disclosed |
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2011-08-18 | — | — | US | disclosed |
| WO-2011086053-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2011-07-21 | — | — | WO | disclosed |
| WO-2011076419-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2011-06-30 | — | — | WO | disclosed |
| WO-2011035159-A1 | ARYL SULPHONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2011-03-24 | — | — | WO | disclosed |
| US-7262206-B2 | Cycloalkyl—containing 5-acylindolinones, the preparation thereof and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-08-28 | — | — | US | disclosed |
| EP-1727812-A1 | NOVEL CYCLOALKYL-CONTAINING 5-ACYLINDOLINONES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICAL PRODUCTS | Boehringer Ingelheim International GmbH (DE) | 2006-12-06 | — | — | EP | disclosed |
| WO-2005087761-A1 | NOVEL CYCLOALKYL-CONTAINING 5-ACYLINDOLINONES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICAL PRODUCTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-09-22 | — | — | WO | disclosed |
| US-20050203104-A1 | Cycloalkyl - containing 5-acylindolinones, the preparation thereof and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250325673-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | DRD2 4346/4885BTK 27/4885EPHX1 1684/4885 |
| US-12390451-B2 | Small molecule inhibitor of the JAK family of kinases | JAK2, JAK1, JAK3 | DRD2 4630/4885BTK 26/4885EPHX1 4114/4885 |
| US-20250163061-A1 | INHIBITORS OF MENIN-MLL INTERACTION | MLLT1, MEN1, BMI1 | DRD2 4826/4885BTK 2123/4885EPHX1 1909/4885 |
| US-20250000985-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | DRD2 4346/4885BTK 27/4885EPHX1 1684/4885 |
| US-12421191-B2 | 3-hydroxyoxindole derivatives as CRHR2 antagonist | CRHR2, CRHR1, CRH | DRD2 188/4885BTK 4865/4885EPHX1 515/4885 |
| US-20050203104-A1 | Cycloalkyl - containing 5-acylindolinones, the preparation thereof and their use as medicaments | GSK3B, GSK3A, CSNK1G3 | DRD2 4317/4885BTK 756/4885EPHX1 4367/4885 |
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | CCNY, CCNA1, CCNA2 | DRD2 3564/4885BTK 690/4885EPHX1 650/4885 |
| US-12168057-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | DRD2 4346/4885BTK 27/4885EPHX1 1684/4885 |
| US-12202831-B2 | Small molecule inhibitors of the JAK family of kinases | JAK1, JAK2, JAK3 | DRD2 3323/4885BTK 11/4885EPHX1 3341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.